Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current pharmacotherapy for hepatitis B infection.

M V Galan1, D Boyce, S C Gordon

  • 1Division of Gastroenterology-Hepatology, William Beaumont Hospital, Royal Oak, Michigan 48073, USA.

Expert Opinion on Pharmacotherapy
|October 5, 2001
PubMed
Summary

New oral antiviral therapies offer improved treatment for chronic hepatitis B virus (HBV) infection. Lamivudine is a promising first-line option, but drug resistance necessitates further research into combination therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Scope of Practice for Oral Health Care: Future Transformative Effects.

JDR clinical and translational research·2022
Same author

Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis.

Journal of gastrointestinal cancer·2019
Same author

Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same author

Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States.

Journal of viral hepatitis·2018
Same author

Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.

Alimentary pharmacology & therapeutics·2018
Same author

HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry.

HLA·2017

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B virus (HBV) infection impacts 350 million globally, leading to cirrhosis and liver cancer.
  • Traditional interferon alpha therapy for HBV has suboptimal response rates and significant toxicity, limiting its use in endemic areas.
  • The advent of oral nucleoside and nucleotide agents marks a significant advancement in managing chronic HBV infection.

Purpose of the Study:

  • To review the current landscape of HBV antiviral treatments.
  • To highlight the efficacy and limitations of oral agents like lamivudine.
  • To emphasize the need for novel therapeutic strategies and combination therapies to overcome drug resistance.

Main Methods:

  • Review of existing literature on hepatitis B virus treatments.

Related Experiment Videos

  • Analysis of the clinical data for oral nucleoside and nucleotide analogs.
  • Discussion of emerging drug resistance patterns and potential combination therapies.

    • Main Results:

    • Oral lamivudine demonstrates good efficacy, safety, and rapid HBV DNA reduction, positioning it as a first-line therapy.
    • Emergence of lamivudine-resistant HBV variants is a significant clinical challenge.
    • Adefovir dipivoxil and entecavir show promise as potential adjuncts to lamivudine therapy.

    Conclusions:

    • Oral antiviral agents represent a new era in chronic hepatitis B management.
    • Combination therapies involving lamivudine with agents like adefovir dipivoxil or entecavir may reduce drug resistance.
    • Continued research into novel HBV antiviral agents is critical for developing effective combination treatments.